CXCL10 and COVID-19: Comparative proteomics identified statistically robust overexpression of several inflammatory cytokines, specifically IL6, IL18, CCL7, CXCL10, and CXCL11, which could be targeted to prevent untoward immune-inflammatory effects in COVID-19 patients.